GLPBio

TAPI-1

Catalog No.: GC12344Purity:>98%Synonyms: TAPI
TAPI-1 هو مثبط TACE (ADAM17) ويمنع تساقط العديد من بروتينات سطح الخلية

المنتجات مخصصة للاستخدام البحثي فقط، وليست للاستخدام البشري. نحن لا نبيع للمرضى.


TAPI-1
Cas No.: 163847-77-6
10mM (in 1mL DMSO)In Stock
$653.00
1
1mgIn Stock
$163.00
1
5mgIn Stock
$594.00
1
10mgIn Stock
$1,062.00
1
10mgIn Stock
$1,094.00
1

المراجع (Citations)

1 publicationsمنشورات الباحثين الذين استخدموا هذا المنتج

الوصف (Description)

TAPI-1 is a TACE (tumor necrosis factor-α converting enzyme) inhibitor that blocks the shedding of the extracellular domain of cell membrane proteins (amphiregulin (AREG)) mediated by TACE by inhibiting its proteolytic activity[1, 2]. TAPI-1 is also a metalloproteinase (MMP) inhibitor[3]. TAPI-1 can reduce cellular oxidative stress and the production of inflammatory factors[4].

In vitro, TAPI-1 (0-20µM) treatment of TE-1 and Eca109 cells for 24h inhibited cell viability, migration, and invasion in a dose-dependent manner, and promoted cisplatin-induced apoptosis[5]. TAPI-1 (20µM) treatment of A549 cells for 24h reduced cell proliferation and inhibited EGFR and Notch1 mRNA expression[6]. TAPI-1 (5, 10µM) treatment of NCI-H292 cells for 6 and 24h blocked the shedding of amphiregulin (AREG) from the cell membrane stimulated by diacetyl[7].

In vivo, TAPI-1 (10mg/kg) administered by intraperitoneal injection to mice with Staphylococcus aureus-induced arthritis significantly reduced paw swelling and decreased the concentrations of superoxide, nitric oxide, and hydrogen peroxide in joint tissues[8].

References:
[1] Slack B E, Ma L K, Seah C C. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-α converting enzyme[J]. Biochemical Journal, 2001, 357(3): 787-794.
[2] Liu C, Xu P, Lamouille S, et al. TACE-mediated ectodomain shedding of the type I TGF-β receptor downregulates TGF-β signaling[J]. Molecular cell, 2009, 35(1): 26-36.
[3] Koon H W, Zhao D, Na X, et al. Metalloproteinases and transforming growth factor-α mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes[J]. Journal of Biological Chemistry, 2004, 279(44): 45519-45527.
[4] Bae E H, Kim I J, Choi H S, et al. Tumor necrosis factor α-converting enzyme inhibitor attenuates lipopolysaccharide-induced reactive oxygen species and mitogen-activated protein kinase expression in human renal proximal tubule epithelial cells[J]. The Korean Journal of Physiology & Pharmacology, 2018, 22(2): 135-143.
[5] Gao L, Li L, Zhang D, et al. TAPI-1 exhibits Anti-tumor efficacy in human esophageal squamous cell carcinoma cells via suppression of NF-κB signaling pathway[J]. Digestive Diseases and Sciences, 2024, 69(1): 81-94.
[6] Pancewicz J, Golec P. The effect of TAPI-1 treatment in non-small cell lung cancer cells[J].
[7] Kelly F L, Sun J, Fischer B M, et al. Diacetyl induces amphiregulin shedding in pulmonary epithelial cells and in experimental bronchiolitis obliterans[J]. American journal of respiratory cell and molecular biology, 2014, 51(4): 568-574.
[8] Sultana S, Bishayi B. Potential anti-arthritic and anti-inflammatory effects of TNF-α processing inhibitor-1 (TAPI-1): A new approach to the treatment of S. aureus arthritis[J]. Immunobiology, 2020, 225(2): 151887.

البروتوكول (Protocol)

Cell experiment [1]:

Cell lines

TE-1、Eca109 cells

Preparation Method

TE-1 and Eca109 cells were exposed tovarying doses of TAPI-1 (0, 1.25, 2.5, 5, 10, and 20μM) for 24h, following which, cell viability was determined using CCK-8 assay.

Reaction Conditions

0, 1.25, 2.5, 5, 10, 20μM; 24h

Applications

Following exposure of TAPI-1, TE-1, and Eca109 cell viability was inhibited in a dose dependent manner.
Animal experiment [2]:

Animal models

Adult Swiss albino male mice

Preparation Method

TAPI-1 was diluted in 5% DMSO in sterile saline solution. The final concentration used was 10mg/kg of body weight. The first dose of TAPI-1 was administered intraperitoneally into each mouse 24h after S.aureus infection and repeated at day 4, day 7, day 10 and day 13 post infection. Control mice received a single dose of TAPI-1 two days prior to sacrifice.

Dosage form

10mg/kg; i.p.

Applications

TAPI-1 administration significantly reduced paw swelling in mice with Staphylococcus aureus-induced arthritis. Following TAPI-1 treatment, the concentrations of superoxide, nitric oxide, and hydrogen peroxide were all reduced in the arthritic joints.

References:
[1] Gao L, Li L, Zhang D, et al. TAPI-1 exhibits Anti-tumor efficacy in human esophageal squamous cell carcinoma cells via suppression of NF-κB signaling pathway[J]. Digestive Diseases and Sciences, 2024, 69(1): 81-94.
[2]Sultana S, Bishayi B. Potential anti-arthritic and anti-inflammatory effects of TNF-α processing inhibitor-1 (TAPI-1): A new approach to the treatment of S. aureus arthritis[J]. Immunobiology, 2020, 225(2): 151887.

الخصائص الكيميائية (Chemical Properties)

رقم CAS
163847-77-6
المرادفات
TAPI
الاسم الكيميائي
N1-((R)-1-(((R)-1-((2-aminoethyl)amino)-1-oxopropan-2-yl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)-N4-hydroxy-2-isobutylsuccinamide
SMILES
NCCNC([C@@H](C)NC([C@H](NC(C(CC(C)C)CC(NO)=O)=O)CC1=CC2=CC=CC=C2C=C1)=O)=O
الصيغة الجزيئية
C26H37N5O5
الوزن الجزيئي
499.6
الذوبانية
≥ 24.98mg/mL in DMSO
التخزين
Store at -20°C
إرشادات عامة
اختر مذيبًا مناسبًا وفقًا لبيانات ذوبانية المنتج. بعد التحضير، قسّم المحلول المخزون إلى أجزاء لتجنب دورات التجميد والذوبان المتكررة.
استخدم المحاليل المخزونة خلال 6 أشهر عند حفظها في -80°C، أو خلال شهر واحد عند حفظها في -20°C.
لتحسين الذوبانية، سخّن الأنبوب إلى 37°C وعرّضه للموجات فوق الصوتية لمدة مناسبة.
شروط الشحن
تُشحن عينات التقييم مع عبوات تبريد. وتُشحن الأحجام الأخرى المتاحة في درجة حرارة الغرفة، أو مع عبوات تبريد عند الطلب.

الحاسبات (Calculators)المولارية / التخفيف / الوزن الجزيئي / تحويل الوحدات / تركيبة داخل الجسم الحي / الذوبانية

g/mol

Reviews

Review for TAPI-1

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%